All Articles

A major Florida acquisition reveals a sophisticated new model for senior housing, blending private equity with data-driven operations to meet a demographic boom.

Dynex Capital's 15% dividend yield is a powerful lure for income seekers, but a payout ratio over 100% begs the question: is this a stable return or a risk in disguise?

As HESM preps its Q2 earnings call, the market is watching. Beyond the numbers, it's a test of its fee-based model against Bakken's pulse.

As Par Pacific prepares its Q2 results, investors will scrutinize how it balanced geopolitical oil price spikes with the pivotal launch of its Hawaii renewables plant.

As Hubbell readies its Q2 results, all eyes are on its ability to power the AI boom and grid upgrades. We look beyond the numbers at the strategy behind the surge.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

Amid record production and surging drilling, PrairieSky's results showcase its resilient royalty model and signal renewed investment vigor in Canada's oil patch.

Amid a disciplined SPAC market resurgence, Samos Energy's new fund targets cash-generating assets, signaling a strategic pivot back to energy security.

A new medical report confirms artificial stone dust causes a fatal, fast-acting lung disease, finding safety controls inadequate and sparking calls for a ban.

Astrana Health is betting big on two veteran executives to scale its AI-driven model. This move isn't just about growth—it's about execution in a booming market.

A defiant press release signals the collapse of a major defense deal. Behind the scenes, a battle over monopolies, pricing, and national security.

AB grew AUM to $905B not through market luck, but through inflows. We unpack the strategy, from passive mandates to retail strength, that works in neutral markets.

As Mission Valley Bank marks 25 years, it offers a masterclass in resilience. How a focus on local systems and strategic growth allowed it to thrive, not just survive.

How did a company once dogged by controversy land on TIME's prestigious 'Best Companies' list? The answer reveals the new calculus of corporate value.

The German biotech has slashed its revenue forecast and now projects a major loss, sending a shockwave through the market and raising questions about its health.

Milla Pharmaceuticals' new FDA approval for a vital acidosis drug offers hope for hospitals battling chronic shortages and marks a key strategic win for parent A.forall.

With the strategic hire of top-rated analyst Garik Shmois, D.A. Davidson signals a major push to dominate research in the critical construction sector.

A rare mid-year IRS mileage rate hike to 76 cents isn't just about gas prices. It's a signal of persistent volatility forcing a strategic rethink.

Tech holding company Anshar Labs acquires 18-year-old Dealer World, betting that its deep AI engineering can transform an industry drowning in noise.

Vital Proteins' founder is back, betting on clear protein to be the next big wellness trend. Can a can of protein water change the market and the world?